Our News
All the latest company news, views and insight from the Beckley Psytech team.
Meet our new scientific advisors
We are very excited to announce that Joanna Neill, Professor of Psychopharmacology at the University of Manchester, and Dr Mike Emanuel, former vice president of global clinical operations for EMEA at Johnson & Johnson, are joining our Scientific Ad... Read More
Learning from 50 years of psychedelic progress
Q&A with Beckley Psytech Director & Chair of Scientific Advisory Board, Lady Amanda Feilding. Amanda Feilding has been called the ‘hidden hand’ behind the renaissance of psychedelic science. Her contribution to global drug policy reform and to op... Read More
Pushing the frontiers of psychedelic medicine
Q&A with Beckley Psytech CEO Cosmo Feilding-Mellen
Psychedelics breakthroughs – why now?
We take a deep dive into the stories behind the science
Meet our new Scientific Advisory Board!
Renowned experts bring decades of experience to Beckley Psytech
News article on the Series A round and the involvement of prominent global biotech investors Greg Bailey and Jim Mellon. Features quotes from Marc Wayne, Chairman of Board.
Beckley Psytech appoints renowned psychedelic experts to Scientific Advisory Board
Beckley Psytech, the psychedelic medicine company, has appointed a series of respected figures from the psychiatric and psychedelic research fields to its Scientific Advisory Board, bringing decades of expertise to its research programme.
News article on the Series A round featuring an interview with CEO, Cosmo Feilding Mellen, discussing optimism around drug regulation and encouraging data for psychedelic medicine.
The FT’s daily tech newsletter covers the news of the Series A round, highlighting Richard Reed’s investment and the ambitions for the company in treating depression and addiction.
Beckley Psytech raises £3m to develop ground-breaking psychedelic medicines
Beckley Psytech, the psychedelic medicine company, has raised £3m of Series A funding to develop a pipeline of psychedelic drugs into licensed pharmaceutical medicines for treating psychiatric and neurological diseases. Investors in the round includ... Read More